UBS Group
TLOG

UBS Group’s TetraLogic Pharmaceuticals Corporation TLOG Stock Holding History

UBS Group’s Portfolio TLOG Stock Details TLOG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-27,299
Closed -$4K – 8397
2016
Q3 		$4K Buy
27,299
+24,630
+923% +$5.69K ﹤0.01% 7245
2016
Q2 		$1K Sell
2,669
-13,593
-84% -$3.78K ﹤0.01% 7635
2016
Q1 		$2K Buy
16,262
+14,762
+984% +$4.1K ﹤0.01% 7373
2015
Q4 		$3K Sell
1,500
-2,202
-59% -$3.88K ﹤0.01% 7948
2015
Q3 		$7K Buy
3,702
+323
+10% +$769 ﹤0.01% 7550
2015
Q2 		$8K Sell
3,379
-4,588
-58% -$14.2K ﹤0.01% 7647
2015
Q1 		$35K Sell
7,967
-6,269
-44% -$31.5K ﹤0.01% 6414
2014
Q4 		$69K Buy
+14,236
New +$63.7K ﹤0.01% 6096

Other funds holding TLOG

California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
BWA
Burt Wealth Advisors North Bethesda, Maryland $407M AUM 11.98% 1-Year Est. Return

UBS Group's TLOG Position: Q4 2016 in Review

UBS Group sold out of TetraLogic Pharmaceuticals Corporation (TLOG) in Q4 2016, closing a stake of 27,299 shares — an estimated $4K sold.

UBS Group first reported a position in TLOG in Q4 2014 and held it in 8 quarters. The position peaked at $69K in Q4 2014. 3 funds tracked by Wall St. Rank hold TLOG as of Q4 2016.

  • UBS Group reported no remaining TetraLogic Pharmaceuticals Corporation position as of Q4 2016 after selling out during the quarter.
  • UBS Group sold 27,299 TetraLogic Pharmaceuticals Corporation shares in Q4 2016, an estimated $4K.
  • UBS Group first reported a position in TetraLogic Pharmaceuticals Corporation in Q4 2014 and held it in 8 quarters.
  • UBS Group's TetraLogic Pharmaceuticals Corporation position peaked at $69K in Q4 2014.
  • 3 funds tracked by Wall St. Rank held TetraLogic Pharmaceuticals Corporation as of Q4 2016.

Based on UBS Group's 13F filing for Q4 2016, filed 14 Feb 2017.